Weight-Loss Drugmakers Lobby for Medicare Coverage

The article discusses how adding Ozempic and Mounjaro to federal plans could increase sales of the drugs.

Weight-loss drugmakers lobby Congress to give them access to a massive payday for their blockbuster treatment: Medicare coverage.

Novo Nordisk AS, Eli Lilly & Co. and other companies are making huge profits from new drugs that treat obesity and diabetes. They cost hundreds or even thousands of dollars per month and Medicare does not cover them for obesity treatment. Weight-loss drugs are not covered by the Medicare prescription drug benefit. The 65 million Medicare-insured older and disabled individuals could drive sales higher if this changed.